Satake I, Tari K, Ohwada F, Saitoh T, Negishi T
Nihon Gan Chiryo Gakkai Shi. 1989 Apr 20;24(4):809-16.
Eighteen patients with stages I to III renal cell carcinoma were treated with Neocarzinostatin before, during and after nephrectomy. The mean cumulative dose of Neocarzinostatin was 18.0 mg. With a minimum follow-up period of 57 months (4.8 years), two of 18 patients developed metastasis and both were dead. Of 17 control patients who were observed for 72 months (6.0 years) or more, ten had recurrent disease and eight of them were dead. The 5-year survival rates were 94% for patients who received Neocarzinostatin and 62% for control patients. There was a statistical difference in survival between these two groups. Neocarzinostatin seems to be effective in the prevention of postoperative recurrence of renal cell carcinoma.
18例I至III期肾细胞癌患者在肾切除术之前、术中及术后接受了新制癌菌素治疗。新制癌菌素的平均累积剂量为18.0毫克。在至少57个月（4.8年）的随访期内，18例患者中有2例发生转移且均死亡。在17例观察了72个月（6.0年）或更长时间的对照患者中，10例出现疾病复发，其中8例死亡。接受新制癌菌素治疗的患者5年生存率为94%，对照患者为62%。两组之间的生存率存在统计学差异。新制癌菌素似乎对预防肾细胞癌术后复发有效。
